Skip to content
Biodatica
Start free

Investigator

Neil A Fanger

VIRTICI, LLC · funded by NIDCR, NHLBI

Companies
3

Resolved onto their grants.

Grants
3

Federal awards on file.

Non-dilutive funding
$2.6M

Summed across those awards.

First award
Apr 1, 2022

Latest Sep 19, 2024.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R44

    A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection

    $699k

    Sep 19, 2024NIDCRVIRTICI, LLCNIH RePORTER · 11195532 (opens the source filing in a new tab)

  2. R44

    A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis

    $1000k

    Apr 1, 2022NHLBIVIRTICI, LLCNIH RePORTER · 11116876 (opens the source filing in a new tab)

  3. R44

    A Novel Bispecific Antibody for the Treatment of Idiopathic Pulmonary Fibrosis

    $904k

    Apr 1, 2022NHLBIVIRTICI, LLCNIH RePORTER · 11320898 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources